v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues    
Services $ 60,254 $ 0
Product 53,957 25,530
Total Revenues 114,211 25,530
Operating Expenses    
Research And Development 3,590,053 3,873,079
General And Administrative 2,602,152 1,810,160
Sales And Marketing 1,598,983 427,401
Total Operating Expenses 7,791,188 6,110,640
Operating Loss (7,676,977) (6,085,110)
Other Income (expenses)    
Interest Income 2 1,721
Interest Expense (41,032) (42,181)
Total Other Income (expenses) (41,030) (40,460)
Net Loss (7,718,007) (6,125,570)
Net Loss Attributable To Non-controlling Interest 83,977 9,424
Net Loss Attributable To Volitionrx Limited Stockholders (7,634,030) (6,116,146)
Other Comprehensive (loss) / Income    
Foreign Currency Translation Adjustments (117,904) 134,133
Net Comprehensive Loss $ (7,835,911) $ (5,991,437)
Net Loss Per Share - Basic And Diluted $ (0.14) $ (0.12)
Weighted Average Shares Outstanding    
- Basic And Diluted 53,775,096 50,928,742

Source